Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
Uri Greenbaum, Kris M. Mahadeo, Partow Kebriaei, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

The Role of Cancer-Specific Target Antigens in CAR T Cell Therapy in Hematological Malignancies
Tabish Khan, Naoshad Muhammad, Mohammad Tarique, et al.
Current Tissue Microenvironment Reports (2024) Vol. 5, Iss. 2, pp. 61-67
Closed Access | Times Cited: 15
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
Tracy Rabilloud, Delphine Potier, Saran Pankaew, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 101
Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
Ilias Christodoulou, Won Jin Ho, Andrew Marple, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 12, pp. e003894-e003894
Open Access | Times Cited: 98
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Adam Nelson, Jordan D. Lukacs, Brent Johnston
Cancers (2021) Vol. 13, Iss. 20, pp. 5174-5174
Open Access | Times Cited: 86
Improving CAR T-Cell Persistence
Violena Pietrobon, Lauren A. Todd, Anghsumala Goswami, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10828-10828
Open Access | Times Cited: 73
Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Zhiliang Bai, Bing Feng, Susan McClory, et al.
Nature (2024) Vol. 634, Iss. 8034, pp. 702-711
Open Access | Times Cited: 11
Microphysiological systems for solid tumor immunotherapy: opportunities and challenges
Sara Abizanda-Campo, Marı́a Virumbrales-Muñoz, Mouhita Humayun, et al.
Microsystems & Nanoengineering (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies
Marika Guercio, Simona Manni, Iolanda Boffa, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 40
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Bouchra Ghazi, Adil El Ghanmi, Sarah Kandoussi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells
Mingya Yang, Lei Wang, Ming Ni, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 36
Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?
Alexandra Neaga, Laura Jimbu, Oana Mesaros, et al.
Cancers (2021) Vol. 13, Iss. 15, pp. 3886-3886
Open Access | Times Cited: 30
Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model
Héctor J. Monzó, Kerttu Kalander, Marko Hyytiäinen, et al.
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 11, pp. 1319-1331
Open Access | Times Cited: 11
Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review
Alberto Boretti
European Journal of Pharmacology (2024) Vol. 974, pp. 176618-176618
Closed Access | Times Cited: 4
FDG PET/CT of Atypical Myeloid Sarcoma After CAR T-Cell Therapy
Derek W. R. Gray, Joanna Fair
Clinical Nuclear Medicine (2025)
Closed Access
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
Gabriele Antonarelli, Federica Giugliano, Chiara Corti, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 884-884
Open Access | Times Cited: 25
γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends
Mateus de Souza Barros, Nilberto Dias de Araújo, Fábio Magalhães-Gama, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Pınar Ataca Atilla, Erden Atilla
Translational Oncology (2022) Vol. 22, pp. 101459-101459
Open Access | Times Cited: 18
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Lihong An, Yuehui Lin, Biping Deng, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies
Harjeet Singh, Samer A. Srour, Denái R. Milton, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Barriers to overcoming immunotherapy resistance in glioblastoma
Julia S. Gillette, Elaina J. Wang, Richard S. Dowd, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 9
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
D. Hoelzer, Renato Bassan, Nicolas Boissel, et al.
Annals of Oncology (2023) Vol. 35, Iss. 1, pp. 15-28
Open Access | Times Cited: 8
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
Zhengli Xu, Xiao‐Jun Huang
Cancer Biology and Medicine (2021) Vol. 18, Iss. -
Open Access | Times Cited: 20
A Mathematical Description of the Bone Marrow Dynamics during CAR T-Cell Therapy in B-Cell Childhood Acute Lymphoblastic Leukemia
Alvaro A. Martinez, Salvador Chulián, Cristina Blázquez Goñi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6371-6371
Open Access | Times Cited: 18
Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies
Emmanuel Owusu Ansah, Andy Baah, Emmanuel Boateng Agyenim
Advances in Cell and Gene Therapy (2023) Vol. 2023, pp. 1-9
Open Access | Times Cited: 7
Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy
Chuan Chen, Zehua Sun, Zening Wang, et al.
Antibodies (2024) Vol. 13, Iss. 2, pp. 39-39
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top